WO1996032387A1 - Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent - Google Patents
Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent Download PDFInfo
- Publication number
- WO1996032387A1 WO1996032387A1 PCT/FR1996/000559 FR9600559W WO9632387A1 WO 1996032387 A1 WO1996032387 A1 WO 1996032387A1 FR 9600559 W FR9600559 W FR 9600559W WO 9632387 A1 WO9632387 A1 WO 9632387A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- radical
- carbon atoms
- general formula
- radicals
- phenyl
- Prior art date
Links
- JNJHHKIDNBXPNX-MKICLRROSA-N CC([C@H](C1)O)C([C@@H](C)C([C@](C)([C@H](C[C@H]2OC3)O)[C@H]([C@@H]4C)[C@@]23O)=O)C(C)(C)[C@@]14O Chemical compound CC([C@H](C1)O)C([C@@H](C)C([C@](C)([C@H](C[C@H]2OC3)O)[C@H]([C@@H]4C)[C@@]23O)=O)C(C)(C)[C@@]14O JNJHHKIDNBXPNX-MKICLRROSA-N 0.000 description 1
- PNUGGYXQDMFFMR-UHFFFAOYSA-N C[O]1CCCC1 Chemical compound C[O]1CCCC1 PNUGGYXQDMFFMR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to new taxoids of general formula:
- Z represents a hydrogen atom or a radical of general formula:
- R 1 represents a benzoyl radical optionally substituted by one or more atoms or radicals, identical or different, chosen from halogen atoms and alkyl radicals containing 1 to 4 carbon atoms, alkoxy containing 1 to 4 carbon atoms or trifluoromethyl, thenoyl or furoyl or an R2-O-CO- radical in which R2 represents: - an alkyl radical containing 1 to 8 carbon atoms, alkenyl containing 2 to 8 carbon atoms, alkynyl containing 3 to 8 carbon atoms, cycloalkyl containing 3 to 6 carbon atoms, cycloalkenyl containing 4 to 6 carbon atoms, bicycloalkyl containing 7 to 10 carbon atoms, these radicals being optionally substituted by one or more substituents chosen from halogen atoms and hydroxy radicals, alkoxy containing 1 to 4 carbon atoms, dialkoylamino, each alkyl part of which contains 1 to 4 carbon atom
- phenyl or ⁇ - or ⁇ -naphthyl radical optionally substituted by one or more atoms or radicals chosen from halogen atoms and alkyl radicals containing 1 to 4 carbon atoms or alkoxy containing 1 to 4 carbon atoms or a radical 5-membered aromatic heterocyclic preferably chosen from furyl and thienyl radicals,
- R3 represents a straight or branched alkyl radical containing 1 to 8 carbon atoms, straight or branched alkenyl containing 2 to 8 carbon atoms, straight or branched alkynyl containing 2 to 8 carbon atoms, cycloalkyl containing 3 to 6 carbon atoms, phenyl or ⁇ - or ⁇ -naphthyl optionally substituted by one or more atoms or radicals chosen from halogen atoms and alkyl, alkenyl, alkynyl, aryl, aralkyl, alkoxy, alkylthio, aryloxy, arylthio, hydroxy, hydroxyalkyl, mercapto radicals, formyl, acyl, acylamino, aroylamino, alkoxycarbonylamino, amino, alcoylamino, dialcoylamino, carboxy, alkoxycarbonyl, carbamoyl, alkylcarbamoyl
- R4 represents an alkoxy radical containing 1 to 6 carbon atoms in a straight or branched chain, alkenyloxy containing 3 to 6 carbon atoms in a straight or branched chain, alkynyloxy containing 3 to 6 carbon atoms in a straight or branched chain, cycloalkyloxy containing 3 to 6 carbon atoms, cycloalkenyloxy containing 3 to 6 carbon atoms optionally substituted by one or more halogen atoms or by an alkoxy radical containing 1 to 4 carbon atoms, alkylthio containing 1 to 4 carbon atoms, or a carboxy radical, alkyloxycarbonyl in which the alkyl part contains 1 to 4 carbon atoms, cyano, carbamoyl, N-alkylcarbamoyl or N, N-dialkoylcarbamoyl in which each alkyl part contains 1 to 4 carbon atoms or forms with the nitrogen atom to which it is linked a saturated hetero
- the aryl radicals which can be represented R3 are phenyl or ce- or ⁇ -naphthyl radicals optionally substituted by one or more atoms or radicals chosen from halogen atoms (fluorine, chlorine, bromine, iodine) and alkyl radicals, alkenyls, alkynyls, aryls, arylalkyls, alkoxy, alkylthio.
- halogen atoms fluorine, chlorine, bromine, iodine
- the heterocyclic radicals which can be represented by R3 are aromatic heterocyclic radicals having 5 members and containing one or more atoms, identical or different, chosen from nitrogen, oxygen or sulfur atoms, optionally substituted by one or more substituents, identical or different, chosen from halogen atoms (fluorine, chlorine, bromine, iodine) and alkyl radicals containing 1 to 4 carbon atoms, aryls containing 6 to 10 carbon atoms, alkoxy containing 1 to 4 carbon atoms, aryloxy containing 6 to 10 carbon atoms, amino, alkylamino containing 1 to 4 carbon atoms, dialcoylamino each alkyl part of which contains 1 to 4 carbon atoms, acylamino of which acyl part contains 1 to 4 carbon atoms, alkoxycarbonylamino containing 1 to 4 atoms carbon, acyl containing 1 to 4 carbon atoms, arylcarbonyl of which the aryl part contains 6 to
- the radical R4 represents a straight or branched alkoxy radical containing 1 to 6 carbon atoms optionally substituted by an ethoxy, ethoxy, methyltio, ethylthio, carboxy, methoxycarbonyl, ethoxycarbonyl, cyano, carbamoyl, N-methylcarbamoyl radical, N- ethylcarbamoyl, N, N-dimethylcarbamoyl, N, N-diethylcarbamoyl, N-pyrrolidinocarbonyl, N-piperidinocarbonyl or phenyl.
- the present invention relates to the products of general formula (I) in which Z represents a hydrogen atom or a radical of general formula (II) in which Rj represents a benzoyl radical or an R2-O-CO- radical in which R2 represents a tert-butyl radical and R3 represents an alkyl radical containing 1 to 6 carbon atoms, alkenyl containing 2 to 6 carbon atoms, cycloalkyl containing 3 to 6 carbon atoms, phenyl optionally substituted by one or more atoms or radicals , identical or different chosen from halogen atoms (fluorine, chlorine) and alkyl (methyl), alkoxy (methoxy), dialcoylamino (dimethylamino), acylamino (acetylamino), alkoxycarbonylamino (tert-butoxycarbonylamino) or trifluoromethyl or radical radicals furyl-2 or -3, thienyl-2 or -3 or thiazolyl-2
- the present invention relates to the products of general formula (I) in which Z represents a hydrogen atom or a radical of general formula (II) in which R ⁇ represents a benzoyl radical or a radical R2-O-CO- in which R2 represents a tert-butyl radical and R3 represents an isobutyl, isobutenyl, butenyl, cyclohexyl, phenyl, furyl-2, furyl-3, thienyl-2, thienyl-2, thiazolyl-2 radical , thiazolyle-4 or thiazolyle-5, R4 represents a methoxy or ethoxy radical.
- the new products of general formula (I) in which Z represents a radical of general formula (II) can be obtained by esterification of a product of general formula:
- R ⁇ and R3 are defined as above, or else R5 represents a hydrogen atom and R7 represents a protective group for the hydro function, and either R5 and R7 together form a saturated heterocycle with 5 or 6 members, or a derivative of this acid to obtain an ester of general formula:
- Esterification using an acid of general formula (IV) can be carried out in the presence of a condensing agent (carbodiimide, reactive carbonate) and an activating agent (aminopyridines) in an organic solvent (ether, ester, ketones, nitriles, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons, aromatic hydrocarbons) at a temperature between -10 and 90 ° C.
- a condensing agent carbbodiimide, reactive carbonate
- an activating agent aminopyridines
- organic solvent ether, ester, ketones, nitriles, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons, aromatic hydrocarbons
- Esterification can also be carried out using the acid of general formula (IV) in the form of a symmetrical anhydride, operating in the presence of an activating agent (aminopyridines) in an organic solvent (ethers, esters, ketones, nitriles , aliphatic hydrocarbons, halogenated aliphatic hydrocarbons, aromatic hydrocarbons) at a temperature between 0 and 90 ° C.
- an activating agent aminopyridines
- organic solvent ethers, esters, ketones, nitriles , aliphatic hydrocarbons, halogenated aliphatic hydrocarbons, aromatic hydrocarbons
- the esterification can also be carried out using the acid of general formula (IV) in the form of halide or in the form of mixed anhydride with an aliphatic or aromatic acid, optionally prepared in situ, in the presence of a base (amino tertiary aliphatic) by operating in an organic solvent (ethers, esters, ketones, nitriles, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons, aromatic hydrocarbons) at a temperature between 0 and 80 ° C.
- a base amino tertiary aliphatic
- R6 represents a hydrogen atom and R7 represents a protecting group for the hydroxy function or else R and R7 together form a 5 or 6-membered saturated heterocycle.
- R ⁇ represents a hydrogen atom
- R7 preferably represents a methoxy methyl, 1-ethoxy-ethyl, benzyloxymethyl, trimethylsilyl, triethylsilyl, ⁇ -trimethylsilylethoxymethyl, benzyloxyca-bonyl or tetrahydro-pyrannyl radical.
- R ⁇ and R7 together form a heterocycle this is preferably an oxazolidine ring optionally mono-substituted or gem-disubstituted in position -2.
- the replacement of the protective groups R7 and / or R6 and R7 with hydrogen atoms can be carried out, depending on their nature, as follows: 1) when R represents a hydrogen atom and R7 represents a protective group for the hydroxy function , the replacement of the protective groups by hydrogen atoms is carried out by means of a mineral acid (hydrochloric acid, sulfuric acid, hydrofluoric acid) or organic acid (acetic acid, methanesulfonic acid, trifluoromethanesulfonic acid, p.toluenesulfonic acid ) used alone or as a mixture, operating in an organic solvent chosen from alcohols, ethers, esters, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons, aromatic hydrocarbons or nitriles at a temperature between -10 and 60 ° C,
- Rj is defined as above, Rg and R9, identical or different, represent a hydrogen atom or an alkyl radical containing 1 to 4 carbon atoms, or an aralkyl radical in which the alkyl part contains 1 to 4 carbon atoms and the aryl part preferably represents a phenyl radical optionally substituted by one or more alkoxy radicals containing 1 to 4 carbon atoms, or an aryl radical representing, preferably a phenyl radical optionally substituted by one or more alkoxy radicals containing 1 to 4 carbon atoms, or alternatively Rg represents an alkoxy radical containing 1 to 4 carbon atoms or a trihalomethyl radical such as trichloromethyl or a phenyl radical substituted by a trihalomethyl radical such as trichloromethyl and Ro represents a hydrogen atom, or Rg and Ro form, together with the carbon atom to which they are linked, a ring having 4 to 7 members, the replacement of the protective group formed by R ( ,
- R3, R4 and R5 are defined as above, which is acylated by means of benzoyl chloride in which the phenyl ring is optionally substituted, of thenoyl chloride, of furoyl chloride or of a product of general formula:
- R 2 -O-CO-X (VIII) in which R2 is defined as above and X represents a halogen atom (fluorine, chlorine) or a residue -O-R2 or -O-CO-O-R2, to obtain a product of general formula (I) in which Z represents a radical of general formula (II).
- the product of general formula (V) is treated with formic acid at a temperature in the region of 20 ° C to provide the product of general formula (VII).
- the acylation of the product of general formula (VII) by means of a benzoyl chloride in which the phenyl radical is optionally substituted, of thenoyl chloride or of furoyl chloride or of a product of general formula (VIII ) is carried out in an inert organic solvent chosen from esters such as ethyl acetate, isopropyl acetate or n.butyl acetate and halogenated aliphatic hydrocarbons such as dichloromethane or 1-dichloro, 2 ethane in the presence of a mineral base such as sodium bicarbonate or organic such as triethylamine.
- esters such as ethyl acetate, isopropyl acetate or n.butyl acetate
- halogenated aliphatic hydrocarbons such as dichloromethane or 1-dichloro, 2 ethane in the presence of a mineral base such as sodium bicarbonate or organic such as triethylamine
- the reaction is carried out at a temperature between 0 and 50 ° C, preferably close to 20 ° C. b) when R represents an optionally substituted benzoyl radical, thenoyl or furoyl or an R2O-CO- radical in which R2 is defined as above, Rg represents a hydrogen atom or an alkoxy radical containing 1 to 4 carbon atoms or a radical phenyl substituted by one or more alkoxy radicals containing 1 to 4 carbon atoms and R9 represents a hydrogen atom, the replacement of the protective group formed by Rg and R7 by hydrogen atoms is carried out in the presence of a mineral acid (hydrochloric acid, sulfuric acid) or organic (acetic acid, methanesulfonic acid, trifluoromethanesulfonic acid, p.toluenesulfonic acid) used alone or as a mixture in stoichiometric or catalytic amount, operating in an organic solvent chosen from alcohols, ethers , esters, ali
- R5 represents a trifluoromethanesulfonyloxy radical
- the transformation of the product obtained after deprotection into a cyclopropane derivative is carried out using an alkali metal halide (sodium iodide, potassium fluoride) or an alkali metal azide (azide sodium) or an ammonium salt by operating in an organic solvent chosen from ethers (tetrahydrofuran, diisopropyl ether, methyl t.butyl ether), nitriles (acetonitrile) or aliphatic esters (ethyl acetate) alone or as a mixture at a temperature between 20 ° C and the boiling temperature of the reaction mixture.
- an alkali metal halide sodium iodide, potassium fluoride
- an alkali metal azide azide sodium
- an ammonium salt by operating in an organic solvent chosen from ethers (tetrahydrofuran, diisopropyl ether, methyl
- R ' 3 -Si-Hal (X) in which the symbols R', identical or different, represent an alkyl radical containing 1 to 4 carbon atoms optionally substituted by a phenyl radical, or a phenyl radical, on the 10- deacetyl-baccatin III to obtain a product of general formula:
- OCOC 6 H 5 in which R4 is defined as above, which by treatment with a derivative of trifluoromethanesulfonic acid such as anhydride or N-phenyl trifluoromethanesulfonimide in an inert organic solvent (optionally halogenated aliphatic hydrocarbons, aromatic hydrocarbons) in the presence of an organic base such as an aliphatic tertiary amine (triethylamine) or pyridine at a temperature between -50 and + 20 ° C, to obtain a product of general formula (III) in which R4 is defined as above and R5 represents a trifluoromethanesulfonyloxy radical, which, by optional treatment with an alkali metal halide (sodium iodide, potassium fluoride) or an alkali metal azide (sodium azide) or an ammonium salt by operating in an organic solvent chosen from ethers (tetrahydrofuran, diisopropyl ether, methyl t
- the new products of general formula (I) obtained by implementing the methods according to the invention can be purified according to known methods such as crystallization or chromatography.
- the new products have anti-tumor properties and more particularly an activity on tumors which are resistant to Taxol® or Taxotère®.
- Such tumors include colon tumors which have high expression of the mdr 1 gene (multi-drug resistance gene).
- Multi-drug resistance is a common term referring to the resistance of a tumor to different products with different structures and mechanisms of action.
- Taxoids are generally known to be highly recognized by experimental tumors such as P388 / DOX, a cell line selected for its resistance to doxorubicin (DOX) and which overexpresses mdr 1. The following examples illustrate the present invention.
- the reaction mixture is purified (direct deposition on the column) by chromatography at atmospheric pressure on 50 g of silica (0.063-0.2 mm) contained in a column of 2.5 cm in diameter (elution gradient: ethyl acetate-dichloromethane from 0-100 to 10-90 by volume) by collecting fractions of 10 cm3.
- the fractions containing only the sought product are combined and concentrated to dryness under reduced pressure (0.27 kPa) at 40 ° C for 2 hours.
- the reaction mixture is diluted with 25 cm3 of dichloromethane, washed with twice 5 cm3 of distilled water.
- the organic phase is dried over magnesium sulfate, filtered through sintered glass and then concentrated to dryness under reduced pressure (0.27 kPa) at a temperature in the region of 40 ° C.
- 704 mg of a pale yellow meringue are thus obtained which are purified by chromatography at atmospheric pressure on 70 g of silica (0.063-0.2 mm) contained in a column 2.5 cm in diameter, eluting (gradient d elution: ethyl acetate-dichloromethane from 0-100 to 15-85 by volume), collecting 10 cm 3 fractions.
- the suspension obtained After 5 minutes at a temperature in the region of 20 ° C, the suspension obtained, maintained under an argon atmosphere, is brought to reflux for 3 hours. After cooling to a temperature in the region of 20 ° C, the reaction mixture is filtered through sintered glass lined with celite.
- the aqueous phase is reextracted with twice 5 cm 3 of dichloromethane.
- the organic phases are combined, dried over magnesium sulfate, filtered through sintered glass and concentrated to dryness under reduced pressure (0.27 kPa) at a temperature in the region of 40 ° C. 0.79 g of an orange solid is thus obtained which is purified by chromatography at atmospheric pressure on 50 g of silica (0.063-0.2 mm) contained in a column 2.5 cm in diameter (gradient of elution: ethyl acetate-dichloromethane from 0-100 to 25-75 by volume), collecting 15 cm 3 fractions.
- Acetoxy-4 ⁇ benzoyloxy-2 ⁇ epoxy-5 ⁇ , 20 trihydroxy-l ⁇ , 7 ⁇ , 13 ⁇ methoxy- 10 ⁇ oxo-9 taxene-11 can be prepared as follows:
- the aqueous phase is extracted with three times 80 cm3 of dichloromethane, then twice 80 cm3 of ethyl acetate.
- the organic phases are combined, dried over magnesium sulfate, filtered through magnesium sulfate and concentrated to dryness under reduced pressure (0.27 kPa) at a temperature in the region of 40 ° C. 3.45 g of a yellow meringue are thus obtained which are purified by chromatography at atmospheric pressure on 150 g of silica (0.063-0.2 mm) contained in a column 3.5 cm in diameter, eluting with a methanol-dichloromethane mixture (5-95 by volume), collecting 35 cm3 fractions.
- Acetoxy-4 ⁇ benzoyloxy-2 ⁇ epoxy-5 ⁇ , 20 hydroxy-l ⁇ methoxy-lO ⁇ oxo-9 bis (triethylsilyloxy) -7 ⁇ , 13 ⁇ taxene-11 can be prepared as follows:
- reaction mixture is again cooled to a temperature in the region of 0 ° C., and 125 mg of sodium hydride at 50% by weight in petrolatum oil are added in portions.
- the reaction mixture is diluted with 50 cm3 of dichloromethane, poured onto 50 cm3 of a saturated aqueous solution of ammonium chloride and decanted.
- the aqueous phase is reextracted with twice 30 cm3 of dichloromethane, then the organic phases are combined, washed with 10 cm3 of distilled water, dried over magnesium sulfate, filtered on sintered glass, and concentrated to dryness under reduced pressure (0, 27 kPa) at a temperature close to 40 ° C.
- Acetoxy-4 benzoyloxy-2 ⁇ epoxy-5 ⁇ , 20 dihydroxy-l ⁇ .lO ⁇ oxo-9 bis (triethylsilyloxy) -7 ⁇ , 13 taxene-11 can be prepared as follows:
- the reaction mixture is brought to a temperature in the region of 20 ° C, diluted with 300 cm3 of ethyl acetate and 100 cm3 of distilled water. After decantation, the aqueous phase is reextracted with twice 50 cm3 of ethyl acetate. The organic phases are combined, washed with 50 cm3 of a saturated aqueous solution of sodium chloride, dried over magnesium sulphate, filtered through sintered glass and then concentrated to dryness under reduced pressure (0.27 kPa) at temperature close to 40 ° C.
- the suspension obtained After 10 minutes at a temperature in the region of 20 ° C, the suspension obtained, maintained under an argon atmosphere, is brought to reflux for 2 hours. After cooling to a temperature in the region of 20 ° C, the reaction mixture is diluted with 50 cm3 of ethyl acetate and filtered through sintered glass lined with celite.
- Tert-butoxycarbonylamino-3 hydroxy-2 phenyl-3 propionate- (2R, 3S) acetoxy-4 benzoyloxy-2 ⁇ epoxy-5 ⁇ , 20 hydroxy-l ⁇ ethoxy-lO ⁇ oxo-9 trifluoromethanesulfonyloxy-7 ⁇ taxene-11 yle-13 ⁇ can be prepared as follows: A solution of 423 mg of tert-butoxycarbonyl-3 (4-methoxy phenyl) -2 phenyl-4 oxazolidine- 1,3 carboxylate-5 (2R.4S.5R) of acetoxy-4 benzoyloxy-2 ⁇ epoxy-5 ⁇ , 20 hydroxy-l ⁇ ethoxy-10 ⁇ oxo-9 trifluoromethanesulfonyloxy-7 ⁇ taxene-11 yl-13 ⁇ in 7 cm3 of a 0.1 N solution of hydrochloric ethanol is maintained for 15 hours under an atmosphere of argon at a temperature close to 0 ° C.
- the reaction mixture is diluted with 35 cm3 of dichloromethane, washed with two times 7 cm3 of distilled water and then 7 cm3 of a saturated aqueous solution of sodium chloride.
- the organic phase is dried over magnesium sulfate, filtered through sintered glass and then concentrated to dryness under reduced pressure (2.7 kPa) at a temperature in the region of 40 ° C. 358 mg of a brown solid are thus obtained which are purified by chromatography at atmospheric pressure on 30 g of silica (0.063-0.2 mm) contained in a column 2.5 cm in diameter, eluting (gradient of elution: ethanol-dichloromethane from 1-99 to 5-95 by volume), collecting 10 cm 3 fractions.
- the reaction mixture is purified (direct deposition on the column) by chromatography at atmospheric pressure on 50 g of silica (0.063-0.2 mm) contained in a column of 2.5 cm in diameter, eluting with a methanol-dichloromethane mixture (1-99 by volume), collecting 10 cm 3 fractions.
- the fractions containing only the sought product are combined and concentrated to dryness under reduced pressure (0.27 kPa) at 40 ° C for 2 hours.
- Acetoxy-4 ⁇ benzoyloxy-2-- epoxy-5 ⁇ , 20 dihydroxy-l ⁇ , 13 ⁇ ethoxy-lO ⁇ oxo-9 trifluoromethanesulfonyloxy-7 ⁇ taxene-11 can be prepared as follows:
- the reaction mixture is stirred at a temperature in the region of 0 ° C for 1.5 hours, diluted with 1 cm3 of a methanol-dichloromethane mixture (5-95 by volume), concentrated to dryness under reduced pressure (2.7 kPa) at a temperature close to 30 ° C.
- the crude residue obtained is purified by chromatography at atmospheric pressure on 30 g of silica (0.063-0.2 mm) contained in a column 2.5 cm in diameter, eluting with a methanol-dichloromethane mixture (2-98 by volume) collecting 10 cm3 fractions.
- the fractions containing only the sought product are combined and concentrated to dryness under reduced pressure (2.7 kPa) at 40 ° C for 2 hours.
- Acetoxy-4 benzoyloxy-2 ⁇ epoxy-5 ⁇ , 20 trihydroxy-l ⁇ , 7 ⁇ , 13 ⁇ ethoxy-lO ⁇ oxo-9 taxene-11 (or ethoxy-lO ⁇ deacetoxy-10 baccatin III) can be prepared as follows:
- the reaction mixture is diluted with 40 cm3 of dichloromethane and poured onto a suspension of 40 cm3 of an aqueous solution supersaturated with NaHCO3, maintained at a temperature in the region of 0 ° C.
- the aqueous phase is reextracted with twice 20 cm3 of diethyl ether.
- Acetoxy-4 ⁇ benzoyloxy-2 ⁇ epoxy-5 ⁇ , 20 hydroxy-l ⁇ ethoxy-10 ⁇ oxo-9 bistriethylsilyloxy-7 ⁇ , 13 ⁇ taxene-11 (or ethoxy-10O deacetoxy-10 bistriethylsilyl- 7,13 baccatin III) can be prepared from as follows:
- the reaction mixture is diluted with 100 cm 3 of ethyl acetate, 10 cm 3 of a saturated aqueous solution of ammonium chloride.
- the decanted organic phase is washed with six times 10 cm3 of distilled water, then 10 cm3 of a saturated aqueous solution of sodium chloride, dried over magnesium sulfate, filtered through sintered glass, and concentrated to dryness under reduced pressure (2.7 kPa) at a temperature close to 40 ° C.
- the suspension obtained After 5 minutes at a temperature in the region of 20 ° C, the suspension obtained, maintained under an argon atmosphere, is brought to reflux for 2.5 hours. After cooling to a temperature in the region of 20 ° C., the reaction mixture is filtered through celite. After rinsing the celite with 5 cm3 of ethyl acetate and concentrating the filtrate to dryness under reduced pressure (2.7 kPa) at a temperature in the region of 40 ° C, 81.2 mg of a yellow meringue is obtained, it is purified by preparative thin layer chromatography: 5 Merck preparative plates, Kieselgel 60F254, thickness 0.5 mm, deposit in solution in dichloromethane, eluting with a methanol-dichloromethane mixture (5-95 by volume).
- the reaction mixture is diluted with 50 cm3 of ethyl acetate, washed with 6 cm3 of a saturated aqueous solution of sodium hydrogencarbonate, 6 cm3 of distilled water and then 6 cm3 of a saturated aqueous solution of sodium chloride.
- the organic phase is dried over magnesium sulfate, filtered through sintered glass and then concentrated to dryness under reduced pressure (2.7 kPa) at a temperature in the region of 40 ° C.
- the reaction mixture is purified (direct deposition on the column) by chromatography at atmospheric pressure on 20 g of silica (0.063-0.2 mm) contained in a 2 cm column. diameter, eluting with a methanol-dichloromethane mixture (4-96 by volume), collecting 10 cm 3 fractions.
- the fractions containing only the sought product are combined and concentrated to dryness under reduced pressure (0.27 kPa) at 40 ° C for 2 hours.
- Acetoxy-4 ⁇ benzoyloxy-2 ⁇ epoxy-5 ⁇ , 20 dihydroxy-l ⁇ , 13 ⁇ (propyl-l) oxy-lO ⁇ oxo-9 trifluoromethanesulfonyloxy-7 ⁇ taxene-11 can be prepared as follows:
- the reaction mixture is stirred at a temperature close to 0 ° C for 55 minutes, then diluted with 2 cm3 of a methanol-dichloromethane mixture (10-90 by volume), concentrated to dryness under reduced pressure (2.7 kPa) at a temperature close to 30 ° C.
- the crude residue obtained is purified by chromatography at atmospheric pressure on 20 g of silica (0.063-0.2 mm) contained in a column 2.5 cm in diameter, eluting with dichloromethane, collecting 10 cm 3 fractions.
- the fractions containing only the sought product are combined and concentrated to dryness under reduced pressure (2.7 kPa) at 40 ° C for 2 hours.
- Acetoxy-4 ⁇ benzoyloxy-2 epoxy-5 ⁇ , 20 trihydroxy-l ⁇ , 7 ⁇ , 13 (propyl-1) oxy-lO ⁇ oxo-9 taxene-11 (or (propyl-l) oxy-l ⁇ deacetoxy-10 baccatin III) can be prepared as follows:
- the reaction mixture is diluted with 40 cm3 of dichloromethane and poured into a suspension of 40 cm3 of an aqueous solution supersaturated with sodium hydrogen carbonate, maintained at a temperature in the region of 0 ° C .
- the aqueous phase is reextracted with twice 20 cm 3 of diethyl ether.
- Acetoxy-4 ⁇ benzoyloxy-2 ⁇ epoxy-5 ⁇ , 20 hydroxy-l ⁇ (propyl-1) oxy-lO ⁇ oxo-9 bistriethylsilyloxy-7 ⁇ , 13 ⁇ taxene-11 (or (propyl-1) oxy-lO ⁇ deacetoxy-10 bistriethylsilyl- 7.13 baccatin III) can be prepared as follows:
- the reaction mixture is diluted with 100 cm 3 of ethyl acetate, 10 cm 3 of a saturated aqueous solution of ammonium chloride.
- the decanted organic phase is washed with six times 10 cm3 of distilled water, then 10 cm3 of a saturated aqueous solution of sodium chloride, dried over magnesium sulfate, filtered through sintered glass, and concentrated to dryness under reduced pressure (2 , 7 kPa) at a temperature in the region of 40 ° C.
- Pathological conditions include abnormal cell proliferation of malignant or non-malignant cells of various tissues and / or organs, including, but not limited to, muscle, bone or connective tissue, skin, brain, lungs, sexual organs, the lymphatic or renal systems, the mammary or blood cells, the liver, the apparatus digestive, pancreas and thyroid or adrenal glands.
- pathological conditions may also include psoriasis, solid tumors, ovarian, breast, brain, prostate, colon, stomach, kidney or testicular cancer, Kaposi's sarcoma, cholangiocarcinoma, choriocarcinoma, neuroblastoma, Wilms tumor, Hodgkin's disease, melanomas, multiple myelomas, chronic lymphocytic leukemias, acute or chronic granulocytic lymphomas.
- the new products according to the invention are particularly useful for the treatment of ovarian cancer.
- the products according to the invention can be used to prevent or delay the onset or recurrence of pathological conditions or to treat these pathological conditions.
- the products according to the invention can be administered to a patient in different forms adapted to the chosen route of administration which, preferably, is the parenteral route.
- Parenteral administration includes intravenous, intraperitoneal, intramuscular or subcutaneous administration. More particularly preferred is intraperitoneal or intravenous administration.
- the present invention also includes pharmaceutical compositions which contain at least one product of general formula (I) in a sufficient amount suitable for use in human or veterinary therapy.
- the compositions can be prepared according to the usual methods using one or more pharmaceutically acceptable adjuvants, carriers or excipients. Suitable carriers include diluents, sterile aqueous media and various non-toxic solvents.
- Suitable carriers include diluents, sterile aqueous media and various non-toxic solvents.
- the compositions are in the form of aqueous solutions or suspensions, injectable solutions which may contain emulsifying agents, dyes, preservatives or stabilizers.
- adjuvants or excipients can be determined by the solubility and chemical properties of the product, the particular mode of administration and good pharmaceutical practices.
- aqueous or non-aqueous sterile solutions or suspensions are used.
- nonaqueous solutions or suspensions can be used natural vegetable oils such as oil olive, sesame oil or paraffin oil or injectable organic esters such as ethyl oleate.
- the sterile aqueous solutions can consist of a solution of a pharmaceutically acceptable salt dissolved in water.
- the aqueous solutions are suitable for intravenous administration as long as the pH is suitably adjusted and the isotonicity is achieved, for example, by a sufficient amount of sodium chloride or glucose. Sterilization can be carried out by heating or by any other means which does not alter the composition.
- compositions can contain at least 0.01% of therapeutically active product.
- the amount of active ingredient in a composition is such that a suitable dosage can be prescribed.
- the compositions are prepared in such a way that a unit dose contains from 0.01 to 1000 mg approximately of active product for parenteral administration.
- Therapeutic treatment can be carried out in conjunction with other therapeutic treatments including antineoplastic drugs, monoclonal antibodies, immunological therapies or radiotherapies or modifiers of biological responses.
- Response modifiers include, but are not limited to, lymphokines and cytokines such as interleukins, interferons ( ⁇ , ⁇ or ⁇ ) and TNF.
- chemotherapeutic agents useful in the treatment of disorders due to abnormal cell proliferation include, but are not limited to, alkylating agents such as nitrogen mustards such as mechloretamine, cyclophosphamide, melphalan and chlorambucil, alkyl sulfonates such as busulfan, nitrosoureas such as carmustine, lomustine, semustin and streptozocin, triazenes such as dacarbazine, antimetabolites such as folic acid analogs such as methotrexate, pyrimidine analogs such as fluorouracil and cytarabine, purine analogs like mercaptopurine and thioguanine, natural products like vinca alkaloids like vinblastine, vincristine and vendesine, epipodophyllotoxins like etoposide and teniposide, antibiotics like dactinomycin , daunorubicin, doxorubicin, bleomycin,
- the doses used to implement the methods according to the invention are those which allow a prophylactic treatment or a maximum therapeutic response.
- the doses vary according to the form of administration, the particular product selected and the specific characteristics of the subject to be treated. In general, the doses are those which are therapeutically effective for the treatment of disorders due to abnormal cell proliferation.
- the products according to the invention can be administered as often as necessary to obtain the desired therapeutic effect. Some patients may respond quickly to relatively large or low doses and may require low or no maintenance doses. Generally, low doses will be used at the start of treatment and, if necessary, increasing doses will be administered until an optimum effect is obtained. For other patients it may be necessary to administer maintenance doses 1 to 8 times a day, preferably 1 to 4 times, depending on the physiological needs of the patient concerned. It is also possible that for some patients it is necessary to use only one or two daily administrations. In humans, the doses are generally between 0.01 and
- the doses will generally be between 0.1 and 100 mg / kg and, preferably between 0.5 and 50 mg / kg and, even more specifically between 1 and 10 mg / kg.
- the doses are generally between 0.1 and 50 mg / kg and, preferably between 0.1 and 5 mg / kg and, even more specifically between 1 and 2 mg / kg. It is understood that, in order to choose the most appropriate dosage, the route of administration, the patient's weight, will have to be taken into account. general health, age and any factors that may affect the effectiveness of treatment.
- Example 2 40 mg of the product obtained in Example 1 are dissolved in 1 cm 3 of Emulphor EL 620 and 1 cm 3 of ethanol then the solution is diluted by adding 18 cm 3 of physiological saline.
- composition is administered by infusion for 1 hour by introduction into physiological saline.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK96913578T DK0820448T3 (da) | 1995-04-14 | 1996-04-12 | Nye taxoider, deres fremstilling og farmaceutiske præparater deraf |
DE69608680T DE69608680T2 (de) | 1995-04-14 | 1996-04-12 | Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen |
AT96913578T ATE193533T1 (de) | 1995-04-14 | 1996-04-12 | Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen |
AU56522/96A AU5652296A (en) | 1995-04-14 | 1996-04-12 | Novel taxoids, preparation thereof, and pharmaceutical compo sitions containing same |
EP96913578A EP0820448B1 (fr) | 1995-04-14 | 1996-04-12 | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
CA002214320A CA2214320C (fr) | 1995-04-14 | 1996-04-12 | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
JP53077796A JP4308905B2 (ja) | 1995-04-14 | 1996-04-12 | 新規なタキソイド、その製造及びそれを含有する製薬学的組成物 |
US08/930,814 US5906990A (en) | 1995-04-14 | 1996-04-12 | Taxoids, preparation thereof, and pharmaceutical compositions containing same |
GR20000400102T GR3033591T3 (en) | 1995-04-14 | 2000-06-01 | Novel taxoids, preparation thereof, and pharmaceutical compositions containing same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9504559A FR2732968B1 (fr) | 1995-04-14 | 1995-04-14 | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
FR95/04559 | 1995-04-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996032387A1 true WO1996032387A1 (fr) | 1996-10-17 |
Family
ID=9478163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1996/000559 WO1996032387A1 (fr) | 1995-04-14 | 1996-04-12 | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
Country Status (16)
Country | Link |
---|---|
US (1) | US5906990A (fr) |
EP (1) | EP0820448B1 (fr) |
JP (1) | JP4308905B2 (fr) |
AR (1) | AR002041A1 (fr) |
AT (1) | ATE193533T1 (fr) |
AU (1) | AU5652296A (fr) |
DE (1) | DE69608680T2 (fr) |
DK (1) | DK0820448T3 (fr) |
ES (1) | ES2148758T3 (fr) |
FR (1) | FR2732968B1 (fr) |
GR (1) | GR3033591T3 (fr) |
IL (1) | IL117878A (fr) |
PT (1) | PT820448E (fr) |
TW (1) | TW349095B (fr) |
WO (1) | WO1996032387A1 (fr) |
ZA (1) | ZA962900B (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0982028A1 (fr) * | 1998-08-20 | 2000-03-01 | Aventis Pharma S.A. | Nouvelle utilisation de dérivés de taxoides |
WO2000010547A2 (fr) * | 1998-08-20 | 2000-03-02 | Aventis Pharma S.A. | Nouvelle utilisation de derives taxoides |
EP1050302A1 (fr) * | 1998-03-17 | 2000-11-08 | Aventis Pharma S.A. | Procédé de traitement de la prolifération anormale cellulaire dans le cerveau |
WO2004092151A1 (fr) * | 2003-04-14 | 2004-10-28 | Aventis Pharma S.A. | PROCEDE DE PREPARATION DU 4,10β-DIACETOXY-2α BENZOYLOXY-5β,20-EPOXY-1,13α-DIHYDROXY-9-OXO-19- NORCYCLOPROPA[G]TAX-11-ENE |
US6956124B2 (en) | 2003-04-14 | 2005-10-18 | Aventis Pharma S.A. | Process for the preparation of 4,10β-diacetoxy-2α-benzoyloxy-5β,20-epoxy-1,13α-dihydroxy-9-oxo-19-norcyclopropa[g]tax-11-ene |
WO2010037859A2 (fr) * | 2008-10-02 | 2010-04-08 | Institut Gustave Roussy | Méthodes permettant de prédire ou contrôler si un patient affecté d’un cancer répond à un traitement par une molécule de la famille des taxoïdes |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7360396A (en) | 1995-09-11 | 1997-04-01 | Enzymed, Inc. | Biocatalytic methods for synthesizing and identifying biologically active compounds |
JP2002543127A (ja) * | 1999-05-03 | 2002-12-17 | アベンテイス・フアルマ・ソシエテ・アノニム | 脳内の異常な細胞の増殖を処置する方法 |
US6596737B2 (en) | 2000-02-02 | 2003-07-22 | Fsu Research Foundation, Inc. | C10 carbamoyloxy substituted taxanes |
US6649632B2 (en) * | 2000-02-02 | 2003-11-18 | Fsu Research Foundation, Inc. | C10 ester substituted taxanes |
PL350028A1 (en) * | 2000-02-02 | 2002-10-21 | Univ Florida State Res Found | C10 carbonate substituted taxanes as antitumor agents |
WO2002066448A1 (fr) * | 2001-02-20 | 2002-08-29 | Dabur India Limited | Procede de preparation de paclitaxel (taxol) utilisant un acide 3-(alk-2-ynyloxy) carbonyl-5-oxazolidine carboxylique |
CA2526278A1 (fr) * | 2003-05-20 | 2004-12-02 | Aronex Pharmaceuticals, Inc. | Chimiotherapie combinee comprenant un complexe de platine liposomal |
US7064980B2 (en) * | 2003-09-17 | 2006-06-20 | Sandisk Corporation | Non-volatile memory and method with bit line coupled compensation |
PE20050693A1 (es) * | 2004-02-13 | 2005-09-27 | Univ Florida State Res Found | Taxanos sustituidos con esteres de ciclopentilo en c10 |
US20060189679A1 (en) * | 2005-02-14 | 2006-08-24 | Florida State University Research Foundation, Inc. | C10 cyclopropyl ester substituted taxane compositions |
US20090076127A1 (en) * | 2007-09-19 | 2009-03-19 | Protia, Llc | Deuterium-enriched larotaxel |
JP2011517455A (ja) * | 2008-03-31 | 2011-06-09 | フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド | C(10)エチルエステルおよびc(10)シクロプロピルエステル置換タキサン |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5254580A (en) * | 1993-01-19 | 1993-10-19 | Bristol-Myers Squibb Company | 7,8-cyclopropataxanes |
WO1995009163A1 (fr) * | 1993-09-29 | 1995-04-06 | Rhone-Poulenc Rorer S.A. | Procede de preparation de taxoides |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5294637A (en) * | 1992-07-01 | 1994-03-15 | Bristol-Myers Squibb Company | Fluoro taxols |
FR2698871B1 (fr) * | 1992-12-09 | 1995-02-24 | Rhone Poulenc Rorer Sa | Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent. |
US5395850A (en) * | 1994-03-10 | 1995-03-07 | Bristol-Myers Squibb Company | 6,7-epoxy paclitaxels |
FR2718135B1 (fr) * | 1994-04-05 | 1996-04-26 | Rhone Poulenc Rorer Sa | Procédé de préparation d'hydroxy-7 taxanes. |
-
1995
- 1995-04-14 FR FR9504559A patent/FR2732968B1/fr not_active Expired - Fee Related
-
1996
- 1996-04-10 TW TW085104260A patent/TW349095B/zh active
- 1996-04-11 IL IL11787896A patent/IL117878A/xx not_active IP Right Cessation
- 1996-04-11 ZA ZA962900A patent/ZA962900B/xx unknown
- 1996-04-12 JP JP53077796A patent/JP4308905B2/ja not_active Expired - Fee Related
- 1996-04-12 AR ARP960102178A patent/AR002041A1/es unknown
- 1996-04-12 AT AT96913578T patent/ATE193533T1/de active
- 1996-04-12 AU AU56522/96A patent/AU5652296A/en not_active Abandoned
- 1996-04-12 ES ES96913578T patent/ES2148758T3/es not_active Expired - Lifetime
- 1996-04-12 PT PT96913578T patent/PT820448E/pt unknown
- 1996-04-12 EP EP96913578A patent/EP0820448B1/fr not_active Expired - Lifetime
- 1996-04-12 DK DK96913578T patent/DK0820448T3/da active
- 1996-04-12 WO PCT/FR1996/000559 patent/WO1996032387A1/fr active IP Right Grant
- 1996-04-12 DE DE69608680T patent/DE69608680T2/de not_active Expired - Lifetime
- 1996-04-12 US US08/930,814 patent/US5906990A/en not_active Expired - Lifetime
-
2000
- 2000-06-01 GR GR20000400102T patent/GR3033591T3/el unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5254580A (en) * | 1993-01-19 | 1993-10-19 | Bristol-Myers Squibb Company | 7,8-cyclopropataxanes |
WO1995009163A1 (fr) * | 1993-09-29 | 1995-04-06 | Rhone-Poulenc Rorer S.A. | Procede de preparation de taxoides |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1050302A1 (fr) * | 1998-03-17 | 2000-11-08 | Aventis Pharma S.A. | Procédé de traitement de la prolifération anormale cellulaire dans le cerveau |
WO2000066113A1 (fr) * | 1998-03-17 | 2000-11-09 | Aventis Pharma S.A. | Methode de traitement d'une proliferation de cellules anormales dans le cerveau |
EP0982028A1 (fr) * | 1998-08-20 | 2000-03-01 | Aventis Pharma S.A. | Nouvelle utilisation de dérivés de taxoides |
WO2000010547A2 (fr) * | 1998-08-20 | 2000-03-02 | Aventis Pharma S.A. | Nouvelle utilisation de derives taxoides |
WO2000010547A3 (fr) * | 1998-08-20 | 2000-06-29 | Aventis Pharma Sa | Nouvelle utilisation de derives taxoides |
US6956124B2 (en) | 2003-04-14 | 2005-10-18 | Aventis Pharma S.A. | Process for the preparation of 4,10β-diacetoxy-2α-benzoyloxy-5β,20-epoxy-1,13α-dihydroxy-9-oxo-19-norcyclopropa[g]tax-11-ene |
WO2004092151A1 (fr) * | 2003-04-14 | 2004-10-28 | Aventis Pharma S.A. | PROCEDE DE PREPARATION DU 4,10β-DIACETOXY-2α BENZOYLOXY-5β,20-EPOXY-1,13α-DIHYDROXY-9-OXO-19- NORCYCLOPROPA[G]TAX-11-ENE |
CN1317271C (zh) * | 2003-04-14 | 2007-05-23 | 安万特医药股份有限公司 | 制备4,10β-二乙酰氧基-2α-苯甲酰氧基-5β,20-环氧-1,13α-二羟基-9-氧代-19-降环丙并[g]紫杉-11-烯的方法 |
AU2004230302B2 (en) * | 2003-04-14 | 2010-01-07 | Aventis Pharma S.A. | Process for the preparation of 4,10B-diacetoxy-2a-benzoyloxy-5B,20-epoxy-1,13a-dihydroxy-9-oxo-19-norcyclopropa[g]TAX-11-ene |
AU2004230302B8 (en) * | 2003-04-14 | 2010-05-27 | Aventis Pharma S.A. | Process for the preparation of 4,10B-diacetoxy-2a-benzoyloxy-5B,20-epoxy-1,13a-dihydroxy-9-oxo-19-norcyclopropa[g]TAX-11-ene |
KR101117512B1 (ko) | 2003-04-14 | 2012-03-15 | 아방티 파르마 소시에테 아노님 | 4,10β?디아세톡시?2α?벤조일옥시?5β,20?에폭시?1,13α?디하이드록시?9?옥소?19?노르사이클로프로파[g]탁스?11?엔의 제조 방법 |
WO2010037859A2 (fr) * | 2008-10-02 | 2010-04-08 | Institut Gustave Roussy | Méthodes permettant de prédire ou contrôler si un patient affecté d’un cancer répond à un traitement par une molécule de la famille des taxoïdes |
EP2177630A1 (fr) * | 2008-10-02 | 2010-04-21 | Institut Gustave Roussy | Procédés de prédiction ou de suivi du fait qu'un patient atteint d'un cancer répond à une traitement par une molécule de la famille des taxoïdes |
WO2010037859A3 (fr) * | 2008-10-02 | 2010-06-03 | Institut Gustave Roussy | Méthodes permettant de prédire ou contrôler si un patient affecté d’un cancer répond à un traitement par une molécule de la famille des taxoïdes |
Also Published As
Publication number | Publication date |
---|---|
ZA962900B (en) | 1996-07-30 |
ATE193533T1 (de) | 2000-06-15 |
EP0820448B1 (fr) | 2000-05-31 |
ES2148758T3 (es) | 2000-10-16 |
JP4308905B2 (ja) | 2009-08-05 |
JPH11503443A (ja) | 1999-03-26 |
FR2732968A1 (fr) | 1996-10-18 |
EP0820448A1 (fr) | 1998-01-28 |
TW349095B (en) | 1999-01-01 |
DK0820448T3 (da) | 2000-08-21 |
DE69608680T2 (de) | 2000-10-19 |
AU5652296A (en) | 1996-10-30 |
FR2732968B1 (fr) | 1997-05-16 |
PT820448E (pt) | 2000-09-29 |
AR002041A1 (es) | 1998-01-07 |
GR3033591T3 (en) | 2000-09-29 |
IL117878A0 (en) | 1996-08-04 |
IL117878A (en) | 2001-03-19 |
DE69608680D1 (de) | 2000-07-06 |
US5906990A (en) | 1999-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0817779B1 (fr) | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent | |
CA2238884C (fr) | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent | |
WO1994013654A1 (fr) | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent | |
EP0820448B1 (fr) | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent | |
EP0885208B1 (fr) | Taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent | |
CA2214322C (fr) | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent | |
EP0788492B1 (fr) | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent | |
WO1995033736A1 (fr) | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent | |
EP0764155B1 (fr) | Taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent | |
EP0874838B1 (fr) | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent | |
WO1996001259A1 (fr) | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent | |
WO1996030373A1 (fr) | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent | |
CA2214320C (fr) | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent | |
FR2732340A1 (fr) | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent | |
WO1995033739A1 (fr) | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent | |
WO1996003395A1 (fr) | Taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AU BB BG BR CA CN CZ EE FI GE HU IS JP KP KR LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2214320 Country of ref document: CA Kind code of ref document: A Ref document number: 2214320 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996913578 Country of ref document: EP Ref document number: 08930814 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 1996 530777 Country of ref document: JP Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1996913578 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996913578 Country of ref document: EP |